Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
Holding PYPD?
Track your performance easily
PYPD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.95 - $9.20
Previous Close$3.43
Volume15.99K
Average Volume (3M)7.03K
Market Cap
$23.34M
Enterprise Value$29.81M
Total Cash (Recent Filing)$5.31M
Total Debt (Recent Filing)$11.78M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Feb 05, 2025EPS Estimate
-$1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.69
Shares Outstanding6,803,478
10 Day Avg. Volume11,753
30 Day Avg. Volume7,028
Standard Deviation0.20
R-Squared0.10
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)-11.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.40
Forecast
1Y Price Target
$12.33Price Target Upside247.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
PolyPid News
PremiumCompany Announcements
PolyPid Reports Q3 Results Amid SHIELD II Trial Progress
PremiumCompany Announcements
PolyPid Announces SHIELD II Trial Progress and Financials
PremiumCompany Announcements
PolyPid Announces $8.25 Million Share Sale PlanBulls Say, Bears Say
Bulls Say
Clinical TrialsPolyPid's most advanced pipeline candidate, D-PLEX, is being assessed in a large pivotal clinical trial called SHIELD II.
EfficacyD-PLEX plus standard-of-care (SOC) showed significant efficacy versus SOC alone in patients who underwent abdominal colorectal surgeries with incision lengths greater than 20 centimeters.
PartnershipsPolyPid anticipates at least one ex-U.S. partnership for commercialization of D-PLEX100, as well as a partnership for the broader platform.
Bears Say
Cost UnderestimationSSI rates can be vastly underestimated by only considering 30-days post surgery.
CostsSSI costs for those with commercial insurance through 24 months are up to $165k for a deep incisional + organ space infection, and $44k for superficial infections.
Financial BurdenSSI costs for those with commercial insurance through 24 months are up to $165k for a deep incisional + organ space infection, and $44k for superficial infections.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PYPD FAQ
What was PolyPid Ltd.’s price range in the past 12 months?
PolyPid Ltd. lowest stock price was $2.95 and its highest was $9.20 in the past 12 months.
What is PolyPid Ltd.’s market cap?
Currently, no data Available
When is PolyPid Ltd.’s upcoming earnings report date?
PolyPid Ltd.’s upcoming earnings report date is Feb 05, 2025 which is in 74 days.
How were PolyPid Ltd.’s earnings last quarter?
PolyPid Ltd. released its earnings results on Nov 13, 2024. The company reported -$1.22 earnings per share for the quarter, missing the consensus estimate of -$1.002 by -$0.218.
Is PolyPid Ltd. overvalued?
According to Wall Street analysts PolyPid Ltd.’s price is currently Undervalued.
Does PolyPid Ltd. pay dividends?
PolyPid Ltd. does not currently pay dividends.
What is PolyPid Ltd.’s EPS estimate?
PolyPid Ltd.’s EPS estimate is -$1.08.
How many shares outstanding does PolyPid Ltd. have?
PolyPid Ltd. has 6,803,478 shares outstanding.
What happened to PolyPid Ltd.’s price movement after its last earnings report?
PolyPid Ltd. reported an EPS of -$1.22 in its last earnings report, missing expectations of -$1.002. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of PolyPid Ltd.?
Among the largest hedge funds holding PolyPid Ltd.’s share is ARK Investment Management LLC. It holds PolyPid Ltd.’s shares valued at N/A.
---
PolyPid Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (247.81% Upside)
$12.33 (247.81% Upside)
Hedge Fund Trend
Decreased
By 1.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.54%
12-Months-Change
Fundamentals
Return on Equity
-943.05%
Trailing 12-Months
Asset Growth
-6.39%
Trailing 12-Months
Company Description
PolyPid Ltd.
PolyPid Ltd was incorporated under the laws of Israel and commenced its operations on February 28, 2008. The Company is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.
---
PYPD Earnings Call
Q3 2024
0:00 / 0:00
---
PYPD Stock 12 Month Forecast
Average Price Target
$12.33
▲(247.81% Upside)
Technical Analysis
Best Analysts Covering PYPD
1 Year
1 Year Success Rate
1/26 ratings generated profit
1 Year Average Return
-58.54%
reiterated a buy rating 10 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 3.85% of your transactions generating a profit, with an average return of -58.54% per trade.
---